Hatem Abu Hashim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hatem Abu Hashim has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Essam Ghayaty
Department of Clinical Pharmacology, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
6 shared publicationsMohamed El Rakhawy
Department of Diagnostic Radiology Faculty of Medicine Mansoura University Mansoura Egypt
6 shared publicationsAhmed Badawy
Department of Obstetrics and Gynecology, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
5 shared publicationsOsama Foda
Department of Internal Medicine, Endocrinology Unit, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
5 shared publicationsAlaa Wafa
Division of Diabetes and Endocrinology, Department of Internal Medicine, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publicationsIbrahim Abd Elaal
3 shared publications
Latest Publications
- RetractionOpen Access
- 31 March 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1665
Retraction Note: Does laparoscopic ovarian diathermy change clomiphene-resistant PCOS into clomiphene-sensitive?
- 31 March 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1665
RetractionOpen AccessRetraction Note: Does laparoscopic ovarian diathermy change clomiphene-resistant PCOS into clomiphene-sensitive?
- RetractionOpen Access
- 31 March 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1663
Retraction Note: Letrozole versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial
- 31 March 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1663
RetractionOpen AccessRetraction Note: Letrozole versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial
- Retraction
- 29 March 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1661
Retraction Note: Laparoscopic ovarian diathermy after clomiphene failure in polycystic ovary syndrome: is it worthwhile? A randomized controlled trial
- 29 March 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (5) , 1661
RetractionRetraction Note: Laparoscopic ovarian diathermy after clomiphene failure in polycystic ovary syndrome: is it worthwhile? A randomized controlled trial
- 20 January 2021
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 156 (1) , 71-76
EXPRESSION OF CONCERN: Diagnostic accuracy of the placenta accreta index for placenta accreta spectrum: A prospective study
Objective: To evaluate the role of the placenta accreta index (PAI) score in predicting placenta accreta spectrum (PAS). Methods: In this prospective study, the PAI was applied to 100 third‐trimester pregnant women with at least one previous cesarean delivery (CS) and anterior low‐lying placenta or placenta previa. PAI score was calculated based on placental location, number of CS, abnormal placental lacunae, sagittal smallest myometrial thickness (SSMT), and bridging vessels. Histopathologic confirmation was obtained if hysterectomy was performed. Outcome measures were area under the receiver–operating characteristics curve (AUC‐ROC) and the best cut‐off point of PAI. Regression analysis of the PAI parameters was performed. Results: The PAI had an AUC of 0.84 (95% confidence interval [CI] 0.75–0.91). The best cut‐off point of PAI was 5.37, with a sensitivity of 83.9%, a specificity of 76.3%, a positive predictive value of 85.2%, a negative predictive value of 74.3%, and an accuracy of 81%. PAI parameters showed a significant association with histopathologically proven PAS ( n = 23). The highest odds ratio (OR) was achieved with lacunae grades 2 and 3 (OR 9.22, 95% CI 2.02–42) and the lowest OR with SSMT <1.5 mm (OR 3.78, 95% CI 1.3–10.6). Conclusion: The PAI appears to be a promising predictor of PAS in high‐risk women who required hysterectomy.
- 20 January 2021
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 156 (1) , 71-76
EXPRESSION OF CONCERN: Diagnostic accuracy of the placenta accreta index for placenta accreta spectrum: A prospective study
Objective: To evaluate the role of the placenta accreta index (PAI) score in predicting placenta accreta spectrum (PAS). Methods: In this prospective study, the PAI was applied to 100 third‐trimester pregnant women with at least one previous cesarean delivery (CS) and anterior low‐lying placenta or placenta previa. PAI score was calculated based on placental location, number of CS, abnormal placental lacunae, sagittal smallest myometrial thickness (SSMT), and bridging vessels. Histopathologic confirmation was obtained if hysterectomy was performed. Outcome measures were area under the receiver–operating characteristics curve (AUC‐ROC) and the best cut‐off point of PAI. Regression analysis of the PAI parameters was performed. Results: The PAI had an AUC of 0.84 (95% confidence interval [CI] 0.75–0.91). The best cut‐off point of PAI was 5.37, with a sensitivity of 83.9%, a specificity of 76.3%, a positive predictive value of 85.2%, a negative predictive value of 74.3%, and an accuracy of 81%. PAI parameters showed a significant association with histopathologically proven PAS ( n = 23). The highest odds ratio (OR) was achieved with lacunae grades 2 and 3 (OR 9.22, 95% CI 2.02–42) and the lowest OR with SSMT <1.5 mm (OR 3.78, 95% CI 1.3–10.6). Conclusion: The PAI appears to be a promising predictor of PAS in high‐risk women who required hysterectomy.
- 1 June 2020
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 40 (6) , 842-850
The prevalence of adenomyosis in an infertile population: a cross-sectional study
- 1 June 2020
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 40 (6) , 842-850
The prevalence of adenomyosis in an infertile population: a cross-sectional study
- Open Access
- 15 March 2020
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 18 (2) , 135-144
Laparotomic myomectomy for a huge cervical myoma in a young nulligravida woman: A case report and review of the literature
Background: A huge cervical myoma (rare) in a young woman is a nightmare of every gynecologist owing to the associated technical challenges in performing a myomectomy. Moreover, the 2014 US Food and Drug Administration prohibited power morcellation during laparoscopic myomectomy due to the inadvertent spread of occult malignancy and an increased risk of iatrogenic parasitic leiomyoma negatively affected the overall rate of a minimally invasive surgery. Case: This report described our experience with a case of a huge anterior cervical myoma (473 gr) in a young nulligravida woman who successfully underwent laparotomic myomectomy. After an initial diagnosis by Magnetic resonance imaging (MRI), we performed preoperative ureteric catheterization. The myoma was enucleated following the footsteps of Victor Bonney, the pioneer of myomectomy, combined with simple additional steps. We did not use preoperative gonadotropin-releasing hormone analog, intraoperative vasopressin injection, or uterine artery ligation. A 6-month follow-up MRI revealed an intact cervical canal in midline position with no evidence of residual fibroid. Conclusion: Based on our experience, the review of the relevant literature, and the US Food and Drug Administration's prohibition of power morcellation during laparoscopic myomectomy, a laparotomic myomectomy for a huge cervical myoma still plays a vital role in fertility preservation. We propose the mnemonic "MUSIC" as a helpful guide for a consistent strategy: M (preoperative MRI), U (prophylactic ureteric catheterization), S (shell out the myoma following Bonney's principles i.e. start-up and stay intracapsular), I (immediate suction to clarify dead space) and C (close the cavity by spiraling stitch). Key words: Cervix, Fibroid, Leiomyoma, Myomectomy.
- 15 March 2020
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 18 (2) , 135-144
Open AccessLaparotomic myomectomy for a huge cervical myoma in a young nulligravida woman: A case report and review of the literature
Background: A huge cervical myoma (rare) in a young woman is a nightmare of every gynecologist owing to the associated technical challenges in performing a myomectomy. Moreover, the 2014 US Food and Drug Administration prohibited power morcellation during laparoscopic myomectomy due to the inadvertent spread of occult malignancy and an increased risk of iatrogenic parasitic leiomyoma negatively affected the overall rate of a minimally invasive surgery. Case: This report described our experience with a case of a huge anterior cervical myoma (473 gr) in a young nulligravida woman who successfully underwent laparotomic myomectomy. After an initial diagnosis by Magnetic resonance imaging (MRI), we performed preoperative ureteric catheterization. The myoma was enucleated following the footsteps of Victor Bonney, the pioneer of myomectomy, combined with simple additional steps. We did not use preoperative gonadotropin-releasing hormone analog, intraoperative vasopressin injection, or uterine artery ligation. A 6-month follow-up MRI revealed an intact cervical canal in midline position with no evidence of residual fibroid. Conclusion: Based on our experience, the review of the relevant literature, and the US Food and Drug Administration's prohibition of power morcellation during laparoscopic myomectomy, a laparotomic myomectomy for a huge cervical myoma still plays a vital role in fertility preservation. We propose the mnemonic "MUSIC" as a helpful guide for a consistent strategy: M (preoperative MRI), U (prophylactic ureteric catheterization), S (shell out the myoma following Bonney's principles i.e. start-up and stay intracapsular), I (immediate suction to clarify dead space) and C (close the cavity by spiraling stitch). Key words: Cervix, Fibroid, Leiomyoma, Myomectomy.
- 3 February 2018
- Published by Springer Nature
- p. 195-211
Laparoscopic Ovarian Drilling
- 27 January 2018
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 297 (4) , 859-870
Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials
This systematic review and meta-analysis aimed to compare the effectiveness of unilateral vs. bilateral laparoscopic ovarian drilling (ULOD vs. BLOD) for improving fertility outcomes in infertile women with clomiphene-resistant polycystic ovary syndrome (PCOS) as well as its effect on ovarian reserve.
- 27 January 2018
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 297 (4) , 859-870
Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials
This systematic review and meta-analysis aimed to compare the effectiveness of unilateral vs. bilateral laparoscopic ovarian drilling (ULOD vs. BLOD) for improving fertility outcomes in infertile women with clomiphene-resistant polycystic ovary syndrome (PCOS) as well as its effect on ovarian reserve.
- 1 December 2017
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 219, 45-52
Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials
- 1 December 2017
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 219, 45-52
Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials
- Open Access
- 5 September 2016
- Vol. 10 (3) , 270-277
Aromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?
Orally active aromatase inhibitors (AIs) have gained attention for treatment of infertile women with endometriosis in whom aromatase p450 is aberrantly expressed. This review aimed to critically appraise and summarize the available evidence concerning the use of AIs for management of endometriosis-associated infertility. PubMed was searched to May 2015 with the following key words: endometriosis, infertility and aromatase. Priority was given for randomized controlled trials (RCTs) followed by other study designs. Main outcome measures were as follows: rates of clinical pregnancy, miscarriage and live birth as well as endocrine outcomes. Eighty-two abstracts were screened and six original articles were included. A RCT demonstrated that post-operative letrozole treatment did not improve spontaneous pregnancy rate. Another RCT reported no superiority of letrozole superovulation over clomiphene citrate (each combined with intrauterine insemination) in minimalmild endometriosis and previous laparoscopic treatment. Anastrozole significantly inhibited the growth of endometriotic cells and their estrogen production in culture. In assisted reproductive technology (ART) cycles, dual suppression (Agonist/anastrozole) was tested in a pilot study with a pregnancy rate of 45% however, high pregnancy loss (30%) occurred. A retrospective study showed that letrozole may improve endometrial receptivity in endometriotic patients undergoing in vitro fertilization (IVF). An opposite view from an in vitro study showed lower estradiol production and aromatase expression in cultured granulosa cells from endometriotic women undergoing IVF and marked reduction under letrozole. In conclusion, current evidence is limited. More trials are warranted to enhance our knowledge and provide a clear and unequivocal evidence to guide our clinical management of infertile women with endometriosis using AIs.
- 5 September 2016
- Vol. 10 (3) , 270-277
Open AccessAromatase Inhibitors for Endometriosis-Associated Infertility; Do We Have Sufficient Evidence?
Orally active aromatase inhibitors (AIs) have gained attention for treatment of infertile women with endometriosis in whom aromatase p450 is aberrantly expressed. This review aimed to critically appraise and summarize the available evidence concerning the use of AIs for management of endometriosis-associated infertility. PubMed was searched to May 2015 with the following key words: endometriosis, infertility and aromatase. Priority was given for randomized controlled trials (RCTs) followed by other study designs. Main outcome measures were as follows: rates of clinical pregnancy, miscarriage and live birth as well as endocrine outcomes. Eighty-two abstracts were screened and six original articles were included. A RCT demonstrated that post-operative letrozole treatment did not improve spontaneous pregnancy rate. Another RCT reported no superiority of letrozole superovulation over clomiphene citrate (each combined with intrauterine insemination) in minimalmild endometriosis and previous laparoscopic treatment. Anastrozole significantly inhibited the growth of endometriotic cells and their estrogen production in culture. In assisted reproductive technology (ART) cycles, dual suppression (Agonist/anastrozole) was tested in a pilot study with a pregnancy rate of 45% however, high pregnancy loss (30%) occurred. A retrospective study showed that letrozole may improve endometrial receptivity in endometriotic patients undergoing in vitro fertilization (IVF). An opposite view from an in vitro study showed lower estradiol production and aromatase expression in cultured granulosa cells from endometriotic women undergoing IVF and marked reduction under letrozole. In conclusion, current evidence is limited. More trials are warranted to enhance our knowledge and provide a clear and unequivocal evidence to guide our clinical management of infertile women with endometriosis using AIs.